Stoke Therapeutics (NASDAQ:STOK) Sees Strong Trading Volume

Stoke Therapeutics, Inc. (NASDAQ:STOK) saw strong trading volume on Friday . 658,934 shares were traded during mid-day trading, a decline of 18% from the previous session’s volume of 804,728 shares.The stock last traded at $15.04 and had previously closed at $15.14.

Analysts Set New Price Targets

Several research firms have recently weighed in on STOK. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Wedbush reissued an “outperform” rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Stoke Therapeutics Trading Down 5.7 %

The stock has a 50-day simple moving average of $14.51 and a 200-day simple moving average of $13.08. The company has a market capitalization of $751.84 million, a price-to-earnings ratio of -5.95 and a beta of 0.96.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. The business had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.18 EPS for the current year.

Insider Activity

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the sale, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Redmile Group LLC grew its stake in Stoke Therapeutics by 93.2% during the 1st quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after buying an additional 2,447,543 shares during the last quarter. Lynx1 Capital Management LP grew its stake in Stoke Therapeutics by 40.3% during the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock worth $70,052,000 after buying an additional 1,488,371 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Stoke Therapeutics during the 2nd quarter worth $19,835,000. Baker BROS. Advisors LP grew its stake in Stoke Therapeutics by 65.9% during the 1st quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock worth $45,474,000 after buying an additional 1,338,309 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its stake in Stoke Therapeutics by 426.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock worth $18,741,000 after buying an additional 1,123,500 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.